The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2026 | Consensus recommendations for relapsed/refractory IDH1-mutated AML treatment
Jorge Cortes, MD, The University of Alabama at Birmingham, Birmingham, AL, discusses a recent Delphi consensus paper addressing evidence-based treatment recommendations for patients with relapsed/refractory (R/R) IDH1-mutated acute myeloid leukemia (AML). Dr Cortes reviews the available data supporting the use of ivosidenib and olutasidenib and explains how expert consensus may help guide treatment selection in the absence of direct comparative trials. This interview took place at the 31st Congress of the European Hematology Association (EHA) in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
